Other Commitments:	3 Months Ended
Mar. 31, 2026
Other Commitments:
Other Commitments:	Note 5 – Other Commitments: Employment Agreements On June 8, 2025, Dr. Alan J. Tuchman M.D. resigned as Chief Executive Officer of the Company, effective June 8, 2025. On August 28, 2025, Dr. Tuchman further resigned from his position as a member of the Board and as a member of all committees of the Board on which he served. Dr. Tuchman now serves as the Company’s Chief Medical Officer. In connection with his resignation as Chief Executive Officer, the Company and Dr. Tuchman agreed to reduce Dr. Tuchman’s base monthly salary to $7,500 per month. For the three months ended March 31, 2026 and 2025, the Company paid Dr. Tuchman $22,500 and $37,500, respectively. As noted above in Note 4—Related Party Transactions, on August 14, 2025, the Company entered into the Silverman Compensation Agreement with Mr. Silverman, effective as of July 1, 2025, pursuant to which Mr. Silverman serves as the Company’s Executive Chairman. See Note 4—Related Party Transactions for additional information regarding the Silverman Compensation Agreement. For the three months ended March 31, 2026 and 2025, the Company paid Mr. Silverman $60,000 and $90,000, respectively. Consulting Agreements Consulting Agreement with James Altucher, Z-List Media, OSS Capital LLC and Joseph Jacks The Company continues to recognize expense related to consulting agreements entered into in 2025 with James Altucher and Z-List Media, Inc. and with OSS Capital LLC and Joseph Jacks. During the three months ended March 31, 2026, the Company recognized consulting expense of $398,306 related to these arrangements. No such expense was recognized during the three months ended March 31, 2025. As of March 31, 2026, prepaid consulting expense related to these agreements was $305,000. Additional information regarding these arrangements was previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Contingencies Pursuant to the Separation and Distribution Agreement and Tax Matters Agreement between Neurotrope and Synaptogenix (the “Tax Matters Agreement”), Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix’s (now TAO Synergies Inc.) business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix (now TAO Synergies Inc.) responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix (now TAO Synergies Inc.) against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix (now TAO Synergies Inc.) is held liable, Synaptogenix (now TAO Synergies Inc.) may be temporarily required to bear these losses. As of the reporting date, there are no claims relating to the indemnification agreement.

Other Commitments:

3 Months Ended

Mar. 31, 2026

Note 5 – Other Commitments:

Employment Agreements

On June 8, 2025, Dr. Alan J. Tuchman M.D. resigned as Chief Executive Officer of the Company, effective June 8, 2025. On August 28, 2025, Dr. Tuchman further resigned from his position as a member of the Board and as a member of all committees of the Board on which he served. Dr. Tuchman now serves as the Company’s Chief Medical Officer. In connection with his resignation as Chief Executive Officer, the Company and Dr. Tuchman agreed to reduce Dr. Tuchman’s base monthly salary to $7,500 per month. For the three months ended March 31, 2026 and 2025, the Company paid Dr. Tuchman $22,500 and $37,500, respectively.

As noted above in Note 4—Related Party Transactions, on August 14, 2025, the Company entered into the Silverman Compensation Agreement with Mr. Silverman, effective as of July 1, 2025, pursuant to which Mr. Silverman serves as the Company’s Executive Chairman. See Note 4—Related Party Transactions for additional information regarding the Silverman Compensation Agreement. For the three months ended March 31, 2026 and 2025, the Company paid Mr. Silverman $60,000 and $90,000, respectively.

Consulting Agreements

Consulting Agreement with James Altucher, Z-List Media, OSS Capital LLC and Joseph Jacks

The Company continues to recognize expense related to consulting agreements entered into in 2025 with James Altucher and Z-List Media, Inc. and with OSS Capital LLC and Joseph Jacks. During the three months ended March 31, 2026, the Company recognized consulting expense of $398,306 related to these arrangements. No such expense was recognized during the three months ended March 31, 2025. As of March 31, 2026, prepaid consulting expense related to these agreements was $305,000.

Additional information regarding these arrangements was previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

Contingencies

Pursuant to the Separation and Distribution Agreement and Tax Matters Agreement between Neurotrope and Synaptogenix (the “Tax Matters Agreement”), Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix’s (now TAO Synergies Inc.) business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix (now TAO Synergies Inc.) responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix (now TAO Synergies Inc.) against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix (now TAO Synergies Inc.) is held liable, Synaptogenix (now TAO Synergies Inc.) may be temporarily required to bear these losses. As of the reporting date, there are no claims relating to the indemnification agreement.